Combined dual antiplatelet therapy with ticagrelor and aspirin is associated with better graft patency than their respective monotherapies


eMediNexus    05 January 2018

A prospective, open-label, multicentre DACAB trial presented at the American Heart Association Scientific Sessions compared the efficacy and safety of a ticagrelor-aspirin combination with ticagrelor monotherapy and aspirin monotherapy on saphenous vein graft (SVG) patency administered within a day following coronary artery bypass grafting (CABG) for 12 months. The results showed that the SVG patency rate was highest in patients on aspirin plus ticagrelor followed by ticagrelor alone and aspirin alone (88.7%, 82.8%, 76.5%, respectively).

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.